 |
市場調查報告書
商品編碼
1920866
脈絡膜新生血管市場規模、佔有率和成長分析（按疾病類型、治療類型、給藥途徑、最終用戶、年齡層和地區分類）—2026-2033年產業預測Choroidal Neovascularization Market Size, Share, and Growth Analysis, By Disease Type, By Treatment Type, By Route of Administration, By End User, By Age Group, By Region - Industry Forecast 2026-2033 |
||||||
全球脈絡膜新生血管市場規模預計在 2024 年達到 63 億美元，從 2025 年的 67 億美元成長到 2033 年的 109.2 億美元，在預測期（2026-2033 年）內複合年成長率為 6.3%。
由於老齡化相關疾病的增加和老年人口的不斷成長，脈絡膜新生血管市場正經歷顯著成長。全球趨勢表明，老齡化相關眼科疾病，尤其是可導致脈絡膜新生血管的黃斑部病變，正顯著增加。病例數的激增凸顯了早期診斷和針對老年族群制定的有效治療策略的必要性。先進的影像技術和治療方法創新顯著改善了臨床療效，並提升了視網膜疾病的整體醫療應對能力。此外，促進醫療服務的公平獲取和患者的積極參與也推動了市場擴張。然而，高昂的治療費用和有限的醫療服務取得等挑戰，需要持續的創新和投資，以改善醫療服務，提高受影響人口的醫療可近性。
全球脈絡膜新生血管市場促進因素
全球脈絡膜新生血管市場的主要促進因素之一是老齡化黃斑部病變(AMD) 和其他視網膜疾病盛行率的上升。隨著人口老化，AMD（通常會導致脈絡膜新生血管形成）的發生率正在迅速增加，因此亟需更先進的治療方案。不斷擴大的患者群體推動了對新型治療方法和技術的需求，包括抗 VEGF 注射和雷射治療。此外，人們對眼部健康的日益重視以及診斷技術的進步使得早期發現和早期療育成為可能，進一步促進了市場成長。因此，製藥公司正積極投資研發，以滿足該領域尚未滿足的需求。
限制全球脈絡膜新生血管市場的因素
全球脈絡膜新生血管市場的主要限制因素之一是先進治療方法方法的高成本。許多用於治療該疾病的創新方案，例如抗VEGF注射和雷射治療，往往價格昂貴，且並非所有保險公司都承保。這種經濟障礙可能會限制患者獲得必要的治療，並阻礙市場整體成長。此外，不同地區在治療核准和報銷政策方面的監管和政策差異，也增加了製造商和醫療服務提供者的複雜性，可能減緩新技術的應用，並限制市場擴張。
全球脈絡膜新生血管市場趨勢
全球脈絡膜新生血管市場正經歷深刻的變革時期，這主要得益於抗血管內皮生長因子（VEGF）療法的進步。長效製劑和高效給藥系統等創新正在改變治療模式，減少患者就診次數，提升治療便利性。這種變革不僅改善了治療效果，也提高了患者滿意度，而患者滿意度對於持續治療至關重要。這些趨勢反映了生物製藥研發的持續進展，凸顯了市場的動態特性：新興治療方法和技術進步不斷重塑市場競爭格局，最終改善脈絡膜新生血管的患者照護照護水準。
目錄
介紹
- 調查目標
- 市場定義和範圍
調查方法
- 調查過程
- 二手資料和一手資料方法
- 市場規模估算方法
執行摘要
- 全球市場展望
- 市場主要亮點
- 細分市場概覽
- 競爭格局概述
市場動態與展望
- 總體經濟指標
- 促進因素和機遇
- 限制與挑戰
- 供給面趨勢
- 需求面趨勢
- 波特的分析和影響
關鍵市場考察
- 關鍵成功因素
- 影響市場的因素
- 關鍵投資機會
- 生態系測繪
- 市場吸引力指數（2025）
- PESTEL 分析
- 價值鏈分析
- 定價分析
- 案例研究
- 監管環境
- 技術評估
- 技術評估
- 監管環境
全球脈絡膜新生血管市場規模（按疾病類型和複合年成長率分類）（2026-2033 年）
- 老齡化黃斑部病變
- 病理性近視
- 眼組織胞漿菌病
- 其他視網膜疾病
全球脈絡膜新生血管市場規模（按治療方法和複合年成長率分類）（2026-2033 年）
- 抗 VEGF 療法
- 動態療法
- 皮質類固醇
全球脈絡膜新生血管治療市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）
- 玻璃體內注射
- 口服
- 其他
全球脈絡膜新生血管市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）
- 醫院
- 眼科診所
- 門診手術中心
全球脈絡膜新生血管市場規模（依年齡層分類）及複合年成長率（2026-2033 年）
- 成人版
- 老年人
全球脈絡膜新生血管市場規模及複合年成長率（2026-2033）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
- 拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地區
- 中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區
競爭資訊
- 前五大公司對比
- 主要企業的市場定位（2025 年）
- 主要市場參與者所採取的策略
- 近期市場趨勢
- 公司市佔率分析（2025 年）
- 主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較
主要企業簡介
- Roche
- Novartis
- Bayer
- Regeneron Pharmaceuticals
- AbbVie
- Pfizer
- Santen Pharmaceutical
- Samsung Bioepis
- Amgen
- Biogen
- Kodiak Sciences
- Outlook Therapeutics
- Graybug Vision
- Ocular Therapeutix
- Bausch+Lomb
- Alimera Sciences
- Apellis Pharmaceuticals
- EyePoint Pharmaceuticals
- Genentech
- Alcon
結論與建議
Global Choroidal Neovascularization Market size was valued at USD 6.3 billion in 2024 and is poised to grow from USD 6.7 billion in 2025 to USD 10.92 billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).
The choroidal neovascularization market is witnessing significant growth fueled by the increasing prevalence of age-related diseases and a rising geriatric population. With global aging trends, there is a marked rise in ocular disorders linked to aging, particularly conditions like macular degeneration that lead to choroidal neovascularization. This surge in cases emphasizes the need for early diagnosis and effective treatment strategies tailored for the elderly. Advanced imaging technologies and therapeutic innovations have markedly enhanced clinical outcomes and the overall healthcare response to retinal diseases. Additionally, the push for equitable access to care and active patient participation is propelling market expansion. However, challenges such as high treatment costs and limited healthcare access necessitate ongoing innovation and investment to improve care delivery and affordability for affected populations.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Choroidal Neovascularization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Choroidal Neovascularization Market Segments Analysis
Global Choroidal Neovascularization Market is segmented by Disease Type, Treatment Type, Route of Administration, End User, Age Group and region. Based on Disease Type, the market is segmented into Age-related Macular Degeneration, Pathologic Myopia, Ocular Histoplasmosis and Other Retinal Disorders. Based on Treatment Type, the market is segmented into Anti-VEGF Therapy, Photodynamic Therapy and Corticosteroids. Based on Route of Administration, the market is segmented into Intravitreal Injection, Oral and Others. Based on End User, the market is segmented into Hospitals, Ophthalmology Clinics and Ambulatory Surgical Centers. Based on Age Group, the market is segmented into Adult and Geriatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Choroidal Neovascularization Market
One key market driver for the global choroidal neovascularization market is the rising prevalence of age-related macular degeneration (AMD) and other retinal disorders. As populations age, the incidence of AMD, which often leads to choroidal neovascularization, has surged, necessitating advanced treatment options. This growing patient base has spurred demand for novel therapies and technologies, including anti-VEGF injections and laser treatments. Additionally, increased awareness surrounding eye health and advancements in diagnostic techniques are enhancing early detection and intervention, further fueling market growth. Consequently, pharmaceutical companies are actively investing in research and development to address the unmet medical needs in this segment.
Restraints in the Global Choroidal Neovascularization Market
One key market restraint for the global choroidal neovascularization market is the high cost of advanced treatments and therapies. Many innovative solutions for managing this condition, including anti-VEGF injections and laser therapies, are often expensive and may not be covered by all insurance providers. This financial barrier can limit patient access to essential care and hinder overall market growth. Additionally, varying regulations across different regions regarding treatment approvals and reimbursement policies can add complexity for manufacturers and healthcare providers, potentially stalling the adoption of new technologies and limiting market expansion.
Market Trends of the Global Choroidal Neovascularization Market
The Global Choroidal Neovascularization market is experiencing a significant shift driven by advancements in anti-VEGF therapies. Innovations such as longer-acting formulations and more efficient delivery systems are transforming treatment practices, allowing for fewer clinic visits and enhancing patient convenience. This evolution not only improves therapeutic outcomes but also boosts patient satisfaction, which is critical for treatment adherence. As a reflection of ongoing biopharmaceutical research and development, these trends highlight the market's dynamic nature, where emerging therapies and technological advancements continuously shape the competitive landscape, ultimately leading to improved patient care and outcomes in managing choroidal neovascularization.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index, 2025
- PESTEL Analysis
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Regulatory Landscape
- Technology Assessment
- Technology Assessment
- Regulatory Landscape
Global Choroidal Neovascularization Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Age-related Macular Degeneration
- Pathologic Myopia
- Ocular Histoplasmosis
- Other Retinal Disorders
Global Choroidal Neovascularization Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Anti-VEGF Therapy
- Photodynamic Therapy
- Corticosteroids
Global Choroidal Neovascularization Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravitreal Injection
- Oral
- Others
Global Choroidal Neovascularization Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers
Global Choroidal Neovascularization Market Size by Age Group & CAGR (2026-2033)
- Market Overview
- Adult
- Geriatric
Global Choroidal Neovascularization Market Size & CAGR (2026-2033)
- North America (Disease Type, Treatment Type, Route of Administration, End User, Age Group)
- US
- Canada
- Europe (Disease Type, Treatment Type, Route of Administration, End User, Age Group)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Disease Type, Treatment Type, Route of Administration, End User, Age Group)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Disease Type, Treatment Type, Route of Administration, End User, Age Group)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Disease Type, Treatment Type, Route of Administration, End User, Age Group)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Santen Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Bioepis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kodiak Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Outlook Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Graybug Vision
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ocular Therapeutix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch + Lomb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alimera Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apellis Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- EyePoint Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alcon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
